Tags

Type your tag names separated by a space and hit enter

Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.
Int Immunopharmacol. 2020 Aug; 85:106683.II

Abstract

BACKGROUND

Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the robustness of neutrophil to CD4+ lymphocyte ratio (NCD4LR) in predicting the negative conversion time (NCT) of SARS-CoV-2 in COVID-19 patients.

METHODS

Univariate and multivariate analysis were conducted to evaluate the independency of NCD4LR in predicting NCT. Receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were used to assess the diagnostic accuracy.

RESULTS

Compared with low NCD4LR patients, patients with high NCD4LR had an older age; higher incidence of fever, fatigue, chest distress/breath shortness, severer disease assessment on admission; higher levels of inflammatory indicators; low levels of lymphocyte subsets, and a longer NCT. Multivariate analysis also identified NCD4LR as an independent risk factor for delayed NCT. ROC analysis showed that NCD4LR had a better performance than neutrophil to lymphocyte ratio in predicting the virus negative conversion within 2 weeks (AUC = 0.772), 3 weeks (AUC = 0.710), 4 weeks (AUC = 0.728), or 5 weeks (AUC = 0.815).

CONCLUSION

This study suggests that NCD4LR is a potential and useful biomarker for predicting the virus negative conversion time in COVID-19 patients. Furthermore, due to the NCDLR value is easily calculated, it can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients.

Authors+Show Affiliations

Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan, China.Department of Infectious Disease, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.Department of Infectious Disease, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan, China.Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan, China.Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan, China. Electronic address: fanndywang@foxmail.com.Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan, China. Electronic address: zhaoqiuwhu@163.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32531713

Citation

Wang, Haizhou, et al. "Neutrophil to CD4+ Lymphocyte Ratio as a Potential Biomarker in Predicting Virus Negative Conversion Time in COVID-19." International Immunopharmacology, vol. 85, 2020, p. 106683.
Wang H, Zhang Y, Mo P, et al. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19. Int Immunopharmacol. 2020;85:106683.
Wang, H., Zhang, Y., Mo, P., Liu, J., Wang, H., Wang, F., & Zhao, Q. (2020). Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19. International Immunopharmacology, 85, 106683. https://doi.org/10.1016/j.intimp.2020.106683
Wang H, et al. Neutrophil to CD4+ Lymphocyte Ratio as a Potential Biomarker in Predicting Virus Negative Conversion Time in COVID-19. Int Immunopharmacol. 2020;85:106683. PubMed PMID: 32531713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19. AU - Wang,Haizhou, AU - Zhang,Yongxi, AU - Mo,Pingzheng, AU - Liu,Jing, AU - Wang,Hongling, AU - Wang,Fan, AU - Zhao,Qiu, Y1 - 2020/06/06/ PY - 2020/05/03/received PY - 2020/05/31/revised PY - 2020/06/04/accepted PY - 2020/6/13/pubmed PY - 2020/7/18/medline PY - 2020/6/13/entrez KW - COVID-19 KW - Negative conversion time KW - Neutrophil to CD4+ lymphocyte ratio KW - SARS-CoV-2 SP - 106683 EP - 106683 JF - International immunopharmacology JO - Int Immunopharmacol VL - 85 N2 - BACKGROUND: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the robustness of neutrophil to CD4+ lymphocyte ratio (NCD4LR) in predicting the negative conversion time (NCT) of SARS-CoV-2 in COVID-19 patients. METHODS: Univariate and multivariate analysis were conducted to evaluate the independency of NCD4LR in predicting NCT. Receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were used to assess the diagnostic accuracy. RESULTS: Compared with low NCD4LR patients, patients with high NCD4LR had an older age; higher incidence of fever, fatigue, chest distress/breath shortness, severer disease assessment on admission; higher levels of inflammatory indicators; low levels of lymphocyte subsets, and a longer NCT. Multivariate analysis also identified NCD4LR as an independent risk factor for delayed NCT. ROC analysis showed that NCD4LR had a better performance than neutrophil to lymphocyte ratio in predicting the virus negative conversion within 2 weeks (AUC = 0.772), 3 weeks (AUC = 0.710), 4 weeks (AUC = 0.728), or 5 weeks (AUC = 0.815). CONCLUSION: This study suggests that NCD4LR is a potential and useful biomarker for predicting the virus negative conversion time in COVID-19 patients. Furthermore, due to the NCDLR value is easily calculated, it can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/32531713/Neutrophil_to_CD4+_lymphocyte_ratio_as_a_potential_biomarker_in_predicting_virus_negative_conversion_time_in_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(20)31400-4 DB - PRIME DP - Unbound Medicine ER -